Skip to content
10-Q

Quarterly Report

Immunome, Inc. IMNM

0001193125-26-219425

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 113.25M sh
Shares Diluted Q1 2026 · Mar 31, 2026 113.14M sh
Shares Diluted Q1 2026 · Mar 31, 2025 79.41M sh
Capex Q1 2026 · Mar 31, 2026 $3M
Capex Q1 2026 · Mar 31, 2025 $3.67M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$58.64M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$53.06M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $582.69M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $653.48M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $257.61M
Stockholders Equity Q1 2026 · Mar 31, 2026 $588.69M
Stockholders Equity Q1 2026 · Dec 31, 2025 $634.34M
Stockholders Equity Q1 2026 · Mar 31, 2025 $307.13M
Stockholders Equity Q1 2026 · Dec 31, 2024 $181.17M
Current Liabilities Q1 2026 · Mar 31, 2026 $27.41M
Current Liabilities Q1 2026 · Dec 31, 2025 $44.99M
Total Liabilities Q1 2026 · Mar 31, 2026 $31.11M
Total Liabilities Q1 2026 · Dec 31, 2025 $48.85M
Current Assets Q1 2026 · Mar 31, 2026 $594.31M
Current Assets Q1 2026 · Dec 31, 2025 $660.78M
Total Assets Q1 2026 · Mar 31, 2026 $619.79M
Total Assets Q1 2026 · Dec 31, 2025 $683.19M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.48
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.52
Eps Basic Q1 2026 · Mar 31, 2026 −$0.48
Eps Basic Q1 2026 · Mar 31, 2025 −$0.52
Sga Expense Q1 2026 · Mar 31, 2026 $12.95M
Sga Expense Q1 2026 · Mar 31, 2025 $10.69M
Rd Expense Q1 2026 · Mar 31, 2026 $46.38M
Rd Expense Q1 2026 · Mar 31, 2025 $36.87M
Net Income Q1 2026 · Mar 31, 2026 −$53.84M
Net Income Q1 2026 · Mar 31, 2025 −$41.64M
Operating Income Q1 2026 · Mar 31, 2026 −$59.33M
Operating Income Q1 2026 · Mar 31, 2025 −$44.64M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $2.93M